What is Zacks Research’s Forecast for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Research analysts at Zacks Research upped their Q1 2025 earnings per share (EPS) estimates for Omnicell in a note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now expects that the company will earn $0.17 per share for the quarter, up from their prior estimate of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at $0.18 EPS, FY2025 earnings at $0.86 EPS and Q1 2026 earnings at $0.27 EPS.

Several other equities research analysts have also recently commented on the stock. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Craig Hallum increased their price target on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Benchmark restated a “buy” rating and issued a $48.00 price target on shares of Omnicell in a research note on Wednesday, October 9th. Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $50.00.

Omnicell Price Performance

Shares of OMCL stock opened at $44.99 on Thursday. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -115.36, a P/E/G ratio of 30.57 and a beta of 0.78. Omnicell has a one year low of $25.12 and a one year high of $55.74. The stock’s fifty day simple moving average is $44.70 and its 200 day simple moving average is $42.66.

Insiders Place Their Bets

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Omnicell

Several institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP lifted its holdings in shares of Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after acquiring an additional 3,570 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Omnicell during the 2nd quarter worth approximately $1,623,000. AQR Capital Management LLC lifted its position in Omnicell by 10.3% during the second quarter. AQR Capital Management LLC now owns 49,071 shares of the company’s stock valued at $1,328,000 after buying an additional 4,572 shares during the period. The Manufacturers Life Insurance Company lifted its position in Omnicell by 6.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,459 shares of the company’s stock valued at $635,000 after acquiring an additional 1,360 shares during the period. Finally, Algert Global LLC boosted its position in shares of Omnicell by 9.8% in the 2nd quarter. Algert Global LLC now owns 51,942 shares of the company’s stock worth $1,406,000 after purchasing an additional 4,617 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.